DOCSLIB.ORG

OIICS Manual 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

4.1-1 SECTION 4.1 Nature of Injury or Illness Index Occupational Injury and Illness Classification Manual 09/07 THIS PAGE INTENTIONALLY LEFT BLANK NATURE CODE INDEX A 0739 Air pressure effects, n.e.c. 0730 Air pressure effects, unspecified 1443 Allergic asthma 2223 Abacterial meningitis 1823 Allergic contact dermatitis 1533 Abdominal hernia 115 Allergic purpura 4175 Abdominal pain, unspecified 4115 Allergic reaction, unspecified 4211 Abnormal blood level of lead 1421 Allergic rhinitis 4212 Abnormal blood level of substances, except 249 Allescheriosis lead 1455 Aluminosis 4212 Abnormal blood-gas level 266 Amebiasis 425 Abnormal electrocardiogram (ECG, EKG) 031* Amputations with bone loss or unspecified 425 Abnormal electroencephalogram (EEG) 0319 Amputations, except fingertip 425 Abnormal electroretinogram (ERG) 0311 Amputations, fingertip 42* Abnormal findings 031* Amputations, medical--due to irreparable 421* Abnormal findings from examination of blood traumatic injuries 4219 Abnormal findings from examination of 0961 Anaphylactic shock with no mention of the blood, n.e.c. underlying injury or illness 4210 Abnormal findings from examination of 257 Ancylostomiasis and necatoriasis blood, unspecified 112 Anemia, aplastic 422 Abnormal findings from examination of urine 112 Anemia, paralytic (toxic) 425 Abnormal findings from function studies 111 Anemia, sickle-cell 426 Abnormal findings from histological and 094 Aneurysm, traumatic immunological studies 1372 Aneurysm--nontraumatic 423 Abnormal findings from other body 1339 Aneurysm of the heart wall, and coronary vessels substances 1332 Angina 424 Abnormal findings from radiological and 1332 Angina pectoris other examination of body structure 0951 Animal or insect bites and stings, venomous 420 Abnormal findings, unspecified 032 Animal or insect bites--nonvenomous 4121 Abnormal involuntary movements 259 Anisakiasis 426 Abnormal karyotype 4219 Anisocytosis 424 Abnormal mammogram results 171 Ankylosis of the joint 4163 Abnormal sputum 129 Anosmia or loss of sense of smell 4129 Abnormality of gait 1231 Anoxic brain damage 081 Abrasions, cuts, bruises 013 Anterior cord syndrome 041 Abrasions, scratches 1229 Anterior horn cell disease 1812 Abscess, skin, and cellulitis 1451 Anthracosis 164 Abscess, breast 2123 Anthrax 155 Abscess, intestinal 4174 Anuria 294 Acariasis (including scabies, chiggers, mites) 521* Anxiety, stress, neurotic disorders 422 Acetonuria 5210 Anxiety, stress, neurotic disorders, 1841 Acne unspecified 1841 Acne varioliformis 5211 Anxiety, over exposure to HIV or other disease 2211 Acquired immune deficiency syndrome (AIDS) 1372 Aortic aneurysms--nontraumatic 1892 Acquired keratoderma 094 Aortic aneurysms, traumatic 2198 Actinomycotic infections 4149 Aphasia 1813 Acute abscess of lymph gland or node 112 Aplasia (lymphadenitis) 112 Aplastic anemia 1359 Acute and subacute endocarditis 0721 Apoplexy, heat 141 Acute bronchitis and bronchiolitis 2212 ARC--AIDS-related complex 1341 Acute cor pulmonale 1379 Arterial embolism--nontraumatic 1813 Acute lymphadenitis (acute abscess of lymph 094 Arterial hematoma gland or node) 1379 Arterial thrombosis--nontraumatic 1359 Acute non-toxic myocarditis 137* Arteries, arterioles, capillaries diseases 1359 Acute pericarditis 1349 Arteriovenous fistula of pulmonary vessels 2221 Acute poliomyelitis 171 Arthritis 1341 Acute pulmonary artery or vein embolism 171 Arthropathies and related disorders (arthritis) 1341 Acute pulmonary artery or vein infarction 1919 Arthropathy--gouty 141 Acute respiratory infections (including 171 Arthropathy--nongouty common cold) 224* Arthropod-borne viral diseases 1351 Acute toxic myocarditis 2249 Arthropod-borne viral diseases, n.e.c. 1422 Adenoids--chronic diseases 2240 Arthropod-borne viral diseases, unspecified 125* Adnexa, eye, vision disorders 1452 Asbestosis 0731 Aero-otitis media 259 Ascariasis 0732 Aerosinusitis 419 Ascites 113 Agranulocytosis or neutropenia 2223 Aseptic meningitis 2211 AIDS--diagnosed 249 Aspergillosis 2212 AIDS-like syndrome, AIDS-related complex 0959 Asphyxia from gas, fumes, and vapors (ARC) 091 Asphyxia, positional 2212 AIDS-related complex (ARC) 091 Asphyxiations/strangulations, suffocations 299 Ainhum 094 Asphyxiation from crushed chest or internal 0962 Air embolism, traumatic injury of the trunk 073 Air pressure effects 1849 Asteatosis—cutis 0738 Air pressure effects, multiple 1443 Asthma, allergic 1461 Asthma, cotton-dust 1443 Asthma, crab 1444 Asthma, extrinsic *Titles -not used for case coding Occupational Injury and Illness Classification Manual 09/07 NATURE CODE INDEX 1449 Asthma, intrinsic 4211 Blood level of lead, abnormal 1451 Asthma, miner's 4212 Blood level of substances except lead, 1449 Asthma, nonallergic abnormal 1461 Asthma, stripper's 2197 Blood poisoning 1495 Atelectasis, collapsed lung 1372 Blood vessel rupture, nontraumatic 1842 Atheroma 094 Blood vessel rupture (trunk), traumatic 1379 Atherosclerosis 099 Blood vessel rupture (nontrunk), traumatic 241 Athlete's foot 1811 Boils 1821 Atopic dermatitis and related conditions 311* Bone or connective tissue neoplasms and 033 Avulsions tumors, malignant 021 Avulsions of joint capsule, ligament, muscle, 3111 Bone, articular cartilage or tendon--traumatic 331 Bone, articular cartilage neoplasms and tumors of unknown properties 321* Bone, connective tissue, and skin B neoplasms,benign 265 Botulism 018 Back fracture--fatal 1361 Brain attack 012 Back fracture--nonfatal 1231 Brain damage, anoxic 0972 Back pain, hurt back 164 Breast abscess 1729 Back spasm--nontraumatic 319 Breast cancer 0972 Back spasm—traumatic 232 Brill-Zinsser disease 021 Back, twisted 011 Broken cartilage 0972 Back went out 012 Broken tooth 0972 Backache--traumatic 141 Bronchiolitis—acute 4219 Bacteremia, unspecified 1449 Bronchiolitis--chronic 21* Bacterial diseases 141 Bronchitis--acute 210 Bacterial diseases, unspecified 1441 Bronchitis--chronic 212* Bacterial diseases, zoonotic 143* Bronchopneumonia 1431 Bacterial pneumonia 1461 Brown lung 1444 Bagassosis 2124 Brucellosis 269 Balantidiasis 082 Bruises and sprains 0732 Barosinusitis 048 Bruises and wounds-surface, multiple 0731 Barotitis 040 Bruises and wounds-surface, unspecified 0732 Barotrauma, sinus 081 Bruises, abrasions, cuts 0731 Barotrauma, otitic 043 Bruises, contusions 239 Bartonellosis 2121 Bubonic plague 3122 Basal cell non-melanoma skin cancer 1379 Buerger's disease 1459 Bauxite fibrosis 1832 Bullous dermatoses 0951 Bee sting 1899 Bumps on skin 299 Behcet's syndrome 05* Burns 1249 Bell's palsy 083 Burns and fractures 0733 Bends 085 Burns and other injuries 164 Benign mammary dysplasias 051 Burns, chemical 32* Benign neoplasms and tumors 052 Burns, electrical 329* Benign neoplasms and tumors of other sites 05* Burns, first, second, or third degree 3299 Benign neoplasms and tumors of other sites, 053 Burns, heat n.e.c. 058 Burns, multiple types 3290 Benign neoplasms and tumors of other sites, 059 Burns, n.e.c. unspecified 059 Burns, radiation 320 Benign neoplasms and tumors, unspecified 1839 Burns, sun 3211 Benign neoplasms of bone and articular 053 Burns, thermal cartilage 050 Burns, unspecified 321* Benign neoplasms of bone, connective tissue, 1731 Bursitis and skin 1461 Byssinosis, Mill fever 3210 Benign neoplasms of bone, connective tissue, and skin, unspecified 3213 Benign neoplasms of the skin C 1456 Berylliosis 251 Bilharziasis 0733 Caisson disease, bends, divers' palsy 422 Biliuria 1891 Callus 032 Bite, animal or insect--nonvenomous 319 Cancer of the breast 0951 Bite, animal or insect--venomous 3* Cancer, Tumors, Neoplasms 043 Black eye 31* Cancers 1451 Black lung 243 Candidiasis 169 Bladder prolapse 259 Capillariasis 246 Blastomycotic infection (including 137* Capillaries, arteries, arterioles diseases paracoccidioidomycosis) 0959 Carbon monoxide poisoning 1255 Blindness, low vision 1811 Carbuncle and furuncle 042 Blisters 31* Carcinomas 05* Blisters from burns 1359 Cardiac arrest, only injury identified 043 Blisters from friction 1359 Cardiac dysrhythmias 119 Blood and blood forming organs diseases, 1331 Cardiac infarction n.e.c. 4159 Cardiac murmurs 042 Blood blisters 1359 Cardiomyopathy 130 Blood clots, nontraumatic, unspecified whether 2132 Cardiovascular syphilis arterial or venous 415* Cardiovascular system symptoms *Titles -not used for case coding Occupational Injury and Illness Classification Manual 09/07 NATURE CODE INDEX 1241 Carpal tunnel syndrome 3112 Connective and other soft tissue cancer 239 Carrion's disease 332 Connective and other soft tissue neoplasms 011 Cartilage tear and tumors of unknown properties 011 Cartilage, fractured or broken 170 Connective tissue and Musculoskeletal 2296 Cat scratch disease system diseases and disorders, unspecified 1254 Cataract 311* Connective tissue or bone neoplasms and 1812 Cellulitis and abscess tumors, malignant 013 Central cord syndrome 321* Connective tissue, bone, and skin 122* Central nervous system degenerative neoplasms, benign diseases 1823 Contact dermatitis, allergic 121* Central nervous system inflammatory 1824 Contact dermatitis, irritant diseases 1822 Contact dermatitis, unspecified 1221 Cerebellar ataxia 06* Contusions, brain 1369 Cerebral artery occulsion 043 Contusions, bruises 061 Cerebral hemorrhages, traumatic 4112 Convulsions, seizures 1360 Cerebral hemorrhages—nontraumatic 1256 Corneal flash burn (welder’s flash) 1361 Cerebrovascular accident (CVA) 1253 Corneal ulcer 136* Cerebrovascular disease 1891 Corns and callosities (including callus, 1369 Cerebrovascular disease, n.e.c. clavus) 1360
Recommended publications
  • The Combined Effect of Sulfanilamide and Penicillin in Treatment Of

    The Combined Effect of Sulfanilamide and Penicillin in Treatment Of

    THE COMBINED EFFECT OF STJLFANILAMIDE AND PENICILLIN IN TREATMENT OF EXPERIMENTAL ERYSIPELOTHRIX RHUSIOPATHIAE INFECTION OF MICE* JOSEPH V. KLAUDER, M.D. AND ANNA M. RULE In a previous communication (1) we reported the results of determinations oi the therapeutic effect of sulfonamide compounds in mice inoculated with Er- ysipelothrix rhusiopathiae. A report was also made of the ineffective use of these compounds in treatment of patients with erysipeloid of Rosenbach and in treatment of one patient with the septicemic form of the infection (2). In our experimental study sulfanilamide, sulfapyridine, sulfathiazole and sul- fadiazine were separately administered to mice orally in doses of 0.2 Gm. per kilogram of body weight. To some the compounds were administered twice daily for two days before inoculation with a virulent strain of Erysipelothrix rhu- siopathiae and twice daily thereafter for six additional days. For others treat- ment was begun four hours after inoculation and then administered twice daily for six additional days; in still others, for eight additional days. It was observed that 12.5 per cent of mice treated before or after the admin- istration of these compounds survived. Additional evidence of some therapeutic effect was the greater percentage (50 per cent) of survival of the animals treated before inoculation and the longer time of survival of animals treated after inocu- lation compared with those of the untreated control group. The therapeutic effect of these compounds is therefore limited. Sulfanilamide and sulfapyridine appeared to give better results than sulfathiazole and sulfadiazine. The thera- peutic effect of these compounds was slightly enhanced when they were employed in conjunction with subcurative injections of immune serum.
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T

    WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
  • Evaluation of Metal and Noise Exposures at an Aircraft Powerplant Parts Manufacturer

    Evaluation of Metal and Noise Exposures at an Aircraft Powerplant Parts Manufacturer

    Evaluation of Metal and Noise Exposures at an Aircraft Powerplant Parts Manufacturer HHE Report No. 2018-0001-3349 April 2019 Authors: Karl D. Feldmann, MS, CIH David A. Jackson, MD Analytical Support: Jennifer Roberts, Maxxam Analytics Desktop Publisher: Jennifer Tyrawski Editor: Cheryl Hamilton Industrial Hygiene Field Assistance: Scott Brueck, Jessica Li, Kevin Moore Logistics: Donnie Booher, Kevin Moore, Mihir Patel Medical Field Assistance: Deborah Sammons, Miriam Siegel Statistical Support: Miriam Siegel Keywords: North American Industry Classification System (NAICS) Code 336412 (Aircraft Engine and Engine Parts Manufacturing), Oregon, Welding, Tungsten Inert Gas, TIG Welding, Inconel, Stainless Steel, Chromium, Hexavalent Chromium, Hex Chrome, Chrome Six, Chrome 6, Chrome IV, Crvi, Cr(VI), Nickel, Cobalt, Biomonitoring, BEI, Noise Disclaimer The Health Hazard Evaluation Program investigates possible health hazards in the workplace under the authority of the Occupational Safety and Health Act of 1970 [29 USC 669a(6)]. The Health Hazard Evaluation Program also provides, upon request, technical assistance to federal, state, and local agencies to investigate occupational health hazards and to prevent occupational disease or injury. Regulations guiding the Program can be found in Title 42, Code of Federal Regulations, Part 85; Requests for Health Hazard Evaluations [42 CFR Part 85]. Availability of Report Copies of this report have been sent to the employer and employee representative at the facility. The state and local health department and the Occupational Safety and Health Administration Regional Office have also received a copy. This report is not copyrighted and may be freely reproduced. Recommended Citation NIOSH [2019]. Evaluation of metal and noise exposures at an aircraft powerplant parts manufacturer.
  • 9.1 Appendix a Minimum Respiratory Protection for Cutting and Welding Processes

    9.1 Appendix a Minimum Respiratory Protection for Cutting and Welding Processes

    Safety Policy and Procedure Policy Number 015 Authorized By: The Cianbro Companies Alan Burton Title: Welding and Cutting Hazard Assessment Program Effective Date: 09/16/95 Page 1 of 12 1 Status 1.1 Update of existing policy, effective 06/03/11. 2 Purpose 2.1 To provide guidelines and requirements to protect team members from the hazards associated with welding, cutting, and burning operations. 3 Applicability 3.1 This policy applies to all subsidiary companies and departments of the Cianbro Companies. 3.2 All organizations are required to comply with the provisions of this policy and procedure. Any deviation, unless spelled out specifically in the policy, requires the permission of the Safety Director or designee. 4 Definitions 4.1 Adequate Ventilation: Used in this policy means any of the following: Local exhaust ventilation is used to capture fumes or in open area with adequate air movement or adequate dilution ventilation with directional air flow away from team member. 4.2 Air Arc (Carbon Arc): A cutting process by which metals are melted by the heat of an arc using a carbon electrode. Molten metal is forced away from the cut by a blast of forced air. 4.3 Bug-O BUG-O Systems Inc.: A manufacturer of a system of drives, carriages, rails and attachments designed to automate welding guns, cutting torches and other hand held tools. 4.4 Cad Welding: An exothermic (gives off heat) welding process that fuses conductors together to form a molecular bond with a current-carrying capacity equal to that of the conductor. Typically used in grounding systems.
  • Are Welders More at Risk of Respiratory Infections?

    Are Welders More at Risk of Respiratory Infections?

    Editorial Against this background, a new paper Thorax: first published as 10.1136/thoraxjnl-2016-208464 on 21 April 2016. Downloaded from Are welders more at risk of respiratory published in this edition of Thorax suggests that welders also have higher rates of upper infections? respiratory infections.15 The findings come from two parallel lines of investigation, David Coggon, Keith T Palmer both focusing on employees at a shipyard in the Middle East. In a cross-sectional survey, welders reported a significantly higher Welding of metals generates a complex mix lobar pneumonia, is clearly affected, but prevalence of respiratory symptoms than of noxious gases and fumes,1 and has been data on mortality by occupation suggest an other manual labourers in winter months linked with various respiratory diseases increased risk also of non-bronchial pneu- (OR 2.31). And in a longitudinal analysis of including metal fume fever,2 asthma,3 monia caused by other microorganisms.56 consultations at the staff medical centre, COPD4 and possibly bronchial carcin- Various mechanisms have been pro- welders consulted for respiratory infections oma.12In addition, there is now strong posed that might explain the hazard. One (mainly of the upper respiratory tract) more and consistent epidemiological evidence theory is that inhaled iron acts as a nutri- frequently than other manual labourers. that welders are at increased risk of infec- ent for microorganisms, promoting their Again, the difference was greater in winter tious, lobar pneumonia. Originally growth.12 This would accord with the (adjusted incidence rate ratio 1.47) than in detected in national analyses of occupa- observations that propensity to infections summer (1.33), but it was significant in tional mortality,5 the hazard was confirmed is increased in patients with sickle cell both seasons.
  • | Oa Tai Ei Rama Telut Literatur

    | Oa Tai Ei Rama Telut Literatur

    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .
  • Toxicological Profile for Zinc

    Toxicological Profile for Zinc

    TOXICOLOGICAL PROFILE FOR ZINC U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry August 2005 ZINC ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. ZINC iii UPDATE STATEMENT A Toxicological Profile for Zinc, Draft for Public Comment was released in September 2003. This edition supersedes any previously released draft or final profile. Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE Mailstop F-32 Atlanta, Georgia 30333 ZINC vi *Legislative Background The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486).
  • NIOSH Research and Demonstration Grants. Fiscal Year 1993 Pdf Icon[PDF – 11.6

    NIOSH Research and Demonstration Grants. Fiscal Year 1993 Pdf Icon[PDF – 11.6

    NIOSH RESEARCH AND DEMONSTRATION GRANTS FISCAL YEAR 1993 NICl5M U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Institute for Occupational Safety and Health Atlanta, Georgia 30333 August 1994 DISCLAIMER Mention of company names or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DliHS(NIOSH} Publication No. 94-131 ii FOREWORD The National Institute for Occupational Safety and Health (NIOSH) is mandated by the provisions of the Occupational Safety and Health Act of 1970 and the Federal Mine Safety and Health Amendments Act of 1977 to conduct research and demonstrations relating to occupational safety and health. Our overall goal is the prevention of illnesses, injuries, and deaths. Recognizing the valuable contributions of extramural scientists to this endeavor, NIOSH sponsors outstanding research through a grants program, which complements the lnstitute's intramural research program. The creativity and special resources available in the scientific community make the grants program a key component in achieving the Nation's goal to have safe jobs and healthy workers. We anticipate an expanded extramural research program in the coming years. To maximize the grants program's usefulness in protecting workers, NIOSH funds projects that are scientifically sound and related to program priorities. We are interested in funding grants that will ultimately be of practical value in solving workplace problems. This report provides a readily available source of information on the status and scope of the research grants program of NIOSH (all active grants during fiscal year 1993: October 1, 1992, to September 30, 1993).
  • Heavy Metals

    Heavy Metals

    Heavy Metals Johanna Feary and Paul Cullinan, Department of Occupational and Environmental Medicine, Imperial College (National Heart and Lung Institute), London, United Kingdom © 2019 Elsevier Inc. All rights reserved. Introduction 2 Individual Heavy Metals 3 Antimony 3 Production and sources of exposure 3 Respiratory toxicity 4 Biological monitoring 4 Arsenic 4 Production and sources of exposure 4 Respiratory toxicity 4 Biological monitoring 4 Cadmium 4 Production and sources of exposure 4 Respiratory toxicity 4 Biological monitoring 5 Chromium 5 Production and sources of exposure 5 Respiratory toxicity 5 Biological monitoring 5 Cobalt 5 Production and sources of exposure 5 Respiratory toxicity 5 Biological monitoring 6 Copper 6 Production and sources of exposure 6 Respiratory toxicity 6 Indium 7 Production and sources of exposure 7 Respiratory toxicity 7 Iridium (See Also Platinum) 7 Production and sources of exposure 7 Respiratory toxicity (see also platinum) 7 Iron 7 Production and sources of exposure 7 Respiratory toxicity 7 Manganese 8 Production and sources of exposure 8 Respiratory toxicity 8 Biological monitoring 8 Mercury 8 Production and sources of exposure 8 Respiratory toxicity 8 Biological monitoring 8 Molybdenum 8 Production and sources of exposure 8 Respiratory toxicity 8 Nickel 8 Production and sources of exposure 8 Respiratory toxicity 8 Biological monitoring 9 Palladium (See Also Platinum) 9 Production and sources of exposure 9 Respiratory toxicity (see also platinum) 9 Platinum and the Platinum Group Metals (PGMs)
  • Occupational Lung Disease Bulletin

    Occupational Lung Disease Bulletin

    Occupational Lung Disease Bulletin Massachusetts Department of Public Health Winter 2017 The objective of the IARC is to identify hazards that are Dear Healthcare Provider, capable of increasing the incidence or severity of malignant neoplasms. The IARC classifications are not Dr. Neil Jenkins co-wrote this Occupational Lung Disease based on the probability that a carcinogen will cause a Bulletin, during his rotation at MDPH from Harvard School cancer or the dose-response, but rather indicate the of Public Health. He brought expertise in welding from a strength of the evidence that an agent can possibly cause materials science and occupational medicine background, a cancer. as well as involvement in welding oversight with the The IARC classifies the strength of the current evidence American Welding Society. that an agent is a carcinogen as: Remember to report cases of suspected work-related lung Group 1 Carcinogenic to humans disease to us by mail, fax (617) 624-5696 or phone (617) Group 2A Probably carcinogenic to humans 624-5632. The confidential reporting form is available on Group 2B Possibly carcinogenic to humans our website at www.mass.gov/dph/ohsp. Group 3 Not classifiable as to carcinogenicity To receive your Bulletin by e-mail, to provide comments, Group 4 Probably not carcinogenic to humans or to contribute an article to the Bulletin, contact us at [email protected] In 1989, welding fume was classified as Group 2B Elise Pechter MPH, CIH because of "limited evidence in humans" and "inadequate evidence in experimental animals." Since that time, an additional 20 case-control studies and nearly 30 cohort studies have provided evidence of increased risk of lung Welding—impact on occupational health cancer from welding fume exposure, even after Neil Jenkins and Elise Pechter accounting for asbestos and tobacco exposures.3 Studies of experimental animals provide added limited evidence 3 Welding joins metals together into a single piece by for lung carcinogenicity.
  • Metal Fume Fever

    Metal Fume Fever

    Safety and Health Fact Sheet No. 25 January 2002 2002 American Welding Society Zn ZnO METAL FUME FEVER OVERVIEW encounter these symptoms, contact a Metal Fume Fever is the name for an illness physician and have a medical examination / that is caused primarily by exposure to zinc evaluation. There is no information in the oxide fume (ZnO) in the workplace. The main literature regarding the effects of long–term cause of this exposure is usually breathing exposure to zinc oxide fumes. the fumes from welding, cutting, or brazing on galvanized metal. Metal Fume Fever is an PERMISSIBLE EXPOSURE LIMIT (PEL) acute allergic condition experienced by The current OSHA standard for zinc oxide many welders during their occupational fume is 5 milligrams of zinc oxide fume per lifetimes. Studies indicate that the most cubic meter of air (mg/m3 ) averaged over an common cause of metal fume fever is eight–hour work shift. NIOSH recommends overexposure to zinc fumes from welding, that the permissible exposure limit be burning, or brazing galvanized steel. Since changed to 5 mg/m3 averaged over a work galvanized steel is more and more common shift of up to 10 hours per day, 40 hours per in industry, the chances of welders having to week, with a Short–Term Exposure Limit work on it are occurring more frequently all (STEL) of 10 mg/m3 averaged over a the time. Other elements, such as copper 15–minute period. Consult the NIOSH and magnesium, may cause similar effects. standard, Criteria Document for Zinc Oxide, listed in the Information Sources for more detailed information.
  • Occupational Injury and Illness Classification Manual

    Occupational Injury and Illness Classification Manual

    Occupational Injury and Illness Classification Manual U.S. Department of Labor Bureau of Labor Statistics September 2007 This document has been modified from its original state by using Adobe Acrobat to make it 508 compliant. 1/8/2009. THIS PAGE INTENTIONALLY LEFT BLANK i OCCUPATIONAL INJURY AND ILLNESS CLASSIFICATION MANUAL Table of Contents Section Page 1. Introduction to the Occupational Injury and Illness Classification Manual 1-1 2. Definitions, Rules of Selection, and Titles and Descriptions 2-1 2.1 Nature of Injury or Illness 2.1-1 2.1.1 Definition, Rules of Selection 2.1-2 2.1.2 Titles and Descriptions 2.1-3 2.2 Part of Body Affected 2.2-1 2.2.1 Definition, Rules of Selection 2.2-2 2.2.2 Titles and Descriptions 2.2-3 2.3 Source of Injury or Illness; Secondary Source of Injury or Illness 2.3-1 2.3.1 Source of Injury Definition, Rules of Selection 2.3-2 2.3.2 Secondary Source of Injury Definition, Rules of Selection 2.3-4 2.3.3 Titles and Descriptions 2.3-6 2.4 Event or Exposure 2.4-1 2.4.1 Definition, Rules of Selection 2.4-2 2.4.2 Titles and Descriptions 2.4-3 3.Code Titles 3-1 3.1 Nature of Injury or Illness 3.1-1 3.2 Part of Body Affected 3.2-1 3.3 Source of Injury or Illness; Secondary Source of Injury or Illness 3.3-1 3.4 Event or Exposure 3.4-1 4.